Rapastinel

DB11801InvestigationalSmall molecule

Rapastinel has been used in trials studying the treatment of Depressive Disorder, Major and Obsessive-Compulsive Disorder (OCD).

Chemical structure of Rapastinel
Mechanism
Curator reviewed
Formula / weight
C18H31N5O6 · 413.475 g/mol (avg)
Code names
GLYX-13

Resolves to

Compound
UNII6A1X56B95ECAS117928-94-6ChEMBLCHEMBL3544917PubChem14539800
Structure
InChIKeyGIBQQARAXHVEGD-BSOLPCOYSA-NSMILESC[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
14+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Rapastinel, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In